Susan Pandya

Susan Pandya, M.D., currently serves as the Chief Medical Officer at Atavistik Bio, overseeing clinical development strategy and execution since September 2025, and as a Board Director at MOMA Therapeutics since February 2025. Prior to these roles, Susan held significant positions at Servier Pharmaceuticals, including Global Head of Oncology Clinical Development and Vice President of Clinical Development, where responsibilities encompassed leadership in late-stage oncology programs and hematology assets across various phases of clinical trials. Before Servier, Susan was Vice President of Clinical Development at Agios Pharmaceuticals, focusing on hematology and oncology indications, and held several roles in medical research and clinical oversight at organizations such as Acceleron Pharma, Harvard Medical School, and Beth Israel Deaconess Medical Center. Educational credentials include a Doctor of Medicine degree from Tufts University School of Medicine and board certifications in Hematology and Oncology.